Bone morphogenetic protein signalling is required for the anti-mitogenic effect of the proteasome inhibitor MG-132 on colon cancer cells

BACKGROUND AND PURPOSE: Inhibition of proteasome has been emerging as a promising approach in pathway-directed cancer therapy. Bone morphogenetic protein (BMP) signalling, which is known to be regulated by the ubiquitin–proteasome pathway in osteoblasts, plays a crucial role in the suppression of ga...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Wu, W K K, Sung, J J Y, Wu, Y C, Li, Z J, Yu, L, Cho, C H
פורמט: Artigo
שפה:Inglês
יצא לאור: Nature Publishing Group 2008
נושאים:
Research Papers
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC2439517/
https://ncbi.nlm.nih.gov/pubmed/18414391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjp.2008.115
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים